Phase III Clinical Study Evaluating the Efficacy and Safety of WPV01 in Patients With Mild/Moderate COVID-19

NCT06197217 ↗

Phase 3 Completed 1350 enrolled Westlake Pharmaceuticals (Hangzhou) Co., Ltd.

RandomizedParallel-groupTriple-blindTreatment

Summary

The study is a multicenter, randomized, double-blind, placebo-controlled efficacy, safety Phase III clinical trial designed to evaluate the efficacy and safety of WPV01 in patients with mild/moderate COVID-19.

Timeline

Start: 2023-06-14
Primary completion: 2023-08-21
Completion: 2023-09-20

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	WPV01	Unknown	200 mg	Oral

Indications

No indication recorded.